Cyclopharm Ltd (ASX: CYC) Share Price and News

Ms Angus has executive managerial and company director experience in the biotechnology, biopharmaceutical, medical device, agritech and healthcare industries. She has long been involved in path to market asset development and commercialization in these industries, notably including the clinical validation of therapeutics to create asset and company valuation uplift. Ms Angus has expertise in corporate strategy, stakeholder and investor engagement and innovative product development. In addition, she has experience in both governance and compliance in listed capital markets. She is a member of the Risk Committee.

Mr McBrayer has more than 35 years of experience in nuclear medicine, healthcare manufacturing, and regulated pharmaceutical businesses. Prior to Cyclopharm, Mr McBrayer was Managing Director of Lipa Pharmaceuticals, a contract manufacturer of over-the-counter healthcare products, where he led large-scale manufacturing, supply-chain, and regulatory operations serving domestic and international brands. Earlier in his career, he held senior management roles with Brambles Cleanaway, gaining experience in complex, asset-heavy service businesses, and with Syncor a provider of radioactive diagnostic and therapeutic pharmaceuticals, where he developed expertise in nuclear medicine logistics, regulatory compliance, and building global healthcare operations to include start-ups. He is a member of the Board Nominations Committee.

Dr King has over 30 years of experience as a clinician, educator and researcher to the Cyclopharm board. Dr. King is Professor of Respiratory Medicine at the Northern Clinical School of the University of Sydney. He is also the Staff Specialist and Head of the Department of Respiratory and Sleep Medicine at Royal North Shore Hospital, where he directs the asthma service and is the Medical Director of the Respiratory Investigation Unit, and the Research Leader of the Airway Physiology and Imaging Group at the Woolcock Institute of Medical Research. In addition, Dr. King supervises PhD and other postgraduate students at the University of Sydney. Dr. King has a current clinical interest in the management of severe pulmonary embolism. His clinical expertise and research are in the mechanisms and management of airways diseases, such as asthma, COPD and bronchiolitis in haemopoietic stem cell transplant recipients, and in the effects of lung cancer surgery.

Mr Cubbin is experienced in nuclear medicine and radiopharmaceutical commercialisation, with a career spanning the full value chain from isotope production through to FDA approval and US market entry. He was Group CFO and a Board Director of Telix Pharmaceuticals through its IPO and the commercialisation of its first FDA-approved product, and prior to that served as Executive Chairman of ANSTO Nuclear Medicine. More recently, he has served as Chairman of both Cyclotek and Oncosil Medical, bringing current and ASX-listed board experience in nuclear medicine and theragnostics.

-

-